Loading...
•
Mar 31, 2021
PTC Therapeutics Q1 2021 Earnings Report
PTC Therapeutics reported strong Q1 2021 results with significant revenue growth and progress in clinical trials.
Key Takeaways
PTC Therapeutics announced a strong first quarter with total revenue of $117.9 million, a 73% increase over Q1 2020. The DMD franchise contributed $90 million, driven by Translarna and Emflaza. The company also highlighted positive preliminary results in the PTC518 Huntington’s disease program.
Total revenue reached $117.9 million, up 73% from Q1 2020.
DMD franchise revenue was $90 million, a 32% increase year-over-year.
PTC518 Phase 1 trial showed dose-dependent reduction of Huntington mRNA.
Evrysdi's first EU sale triggered a $20 million milestone payment.
Revenue by Segment
Forward Guidance
PTC reaffirms its full year 2021 guidance.
Positive Outlook
- Net product revenues for the DMD franchise for the full year 2021 to be between $355 and $375 million.
- PTC anticipates GAAP R&D and SG&A expense for the full year 2021 to be between $825 and $855 million.
- PTC anticipates Non-GAAP R&D and SG&A expense for the full year 2021 to be between $725 and $755 million, excluding estimated non-cash, stock-based compensation expense of $100 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...